MENU
+Compare
PDSB
Stock ticker: NASDAQ
AS OF
May 8, 04:59 PM (EDT)
Price
$1.21
Change
+$0.05 (+4.31%)
Capitalization
55.72M

PDSB PDS Biotechnology Corp Forecast, Technical & Fundamental Analysis

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States... Show more

PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for PDSB with price predictions
May 07, 2025

PDSB's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for PDSB turned positive on April 15, 2025. Looking at past instances where PDSB's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PDSB's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The 10-day moving average for PDSB crossed bullishly above the 50-day moving average on May 01, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where PDSB advanced for three days, in of 257 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 136 cases where PDSB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 07, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PDSB as a result. In of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

PDSB moved below its 50-day moving average on May 06, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PDSB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PDSB broke above its upper Bollinger Band on April 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.843) is normal, around the industry mean (14.238). P/E Ratio (0.000) is within average values for comparable stocks, (62.770). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.866). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.967).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. PDSB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PDSB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

PDSB is expected to report earnings to rise 50.00% to -31 cents per share on May 14

PDS Biotechnology Corp PDSB Stock Earnings Reports
Q1'25
Est.
$-0.31
Q4'24
Beat
by $0.10
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.10
Q1'24
Beat
by $0.07
The last earnings report on March 27 showed earnings per share of -20 cents, beating the estimate of -30 cents. With 258.84K shares outstanding, the current market capitalization sits at 55.72M.
A.I. Advisor
published General Information

General Information

a developer of clinical-stage immunotherapies to treat various early-stage and late-stage cancers which includes head & neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer and related cancers

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
303A College Road
Phone
+1 800 208-3343
Employees
25
Web
https://www.pdsbiotech.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RBOT8.340.31
+3.86%
Vicarious Surgical
RICK40.820.17
+0.42%
RCI Hospitality Holdings
IBN33.80-0.04
-0.12%
ICICI Bank Limited
WHR76.53-0.11
-0.14%
Whirlpool Corp
EXPI7.46-1.21
-13.96%
eXp World Holdings

PDSB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with RXRX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
-2.52%
RXRX - PDSB
47%
Loosely correlated
+0.84%
ATOS - PDSB
46%
Loosely correlated
-2.30%
KYMR - PDSB
45%
Loosely correlated
+1.89%
CRNX - PDSB
44%
Loosely correlated
+2.85%
AXON - PDSB
43%
Loosely correlated
+0.02%
More